CASE REPORT

Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report

Elizabeth Sarah Mayne *, Malcolm Tait, Barry Frank Jacobson, Evashin Pillay and Susan J. Louw

Abstract

Background: Autoimmune paraphenomena, are associated with B-cell lymphoproliferative disorders, including monoclonal gammopathy of uncertain significance. These paraphenomena can rarely include acquired bleeding disorders.

Case presentation: This case study reports an unusual clinical presentation of 2 acquired bleeding disorders, Acquired von Willebrand syndrome (disease) and Acquired Glanzmann’s thrombasthenia, in an elderly patient with monoclonal gammopathy of uncertain significance.

Conclusions: Acquired bleeding disorders are often underdiagnosed and a high degree of clinical suspicion is required. The patient in this study demonstrated platelet aggregometry which was atypical for isolated Glanzmann’s thrombasthenia because of the severe concomitant endogenous decrease in von Willebrand factor. There was an absence of platelet aggregation to all tested agonists including ristocetin. Once the diagnosis was made, however, the patient showed a partial response to intravenous immunoglobulin confirming the immunological pathogenesis in this case. This case highlights the need to consider acquired bleeding disorders in patients with a possible predisposing factor.

Keywords: Acquired von Willebrand syndrome, Monoclonal Gammopathy, Acquired Glanzmann’s Thrombasthenia

Background

Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant B-cell condition characterized by the presence of a monoclonal protein and fewer than 10% clonal plasma cells in the bone marrow with no end-organ damage. MGUS is present in ~ 3% of the general population over 50 years of age with a 1% annual risk of progression to malignant myeloma (MM) [1]. MGUS is associated with an increase in auto-immune paraphenomena including haematological disorders. Autoimmune disorders on the other hand constitute a risk for the development of clonal plasma cells disorders [2].

Von Willebrand Factor (vWF) is a large multimeric glycoprotein which is essential in primary haemostasis, facilitating platelet adhesion at the site of vascular injury. It also increases the half-life of coagulation factor VIII by protecting it from proteolysis in the circulation [3]. Von Willebrand disease (vWD) is a primary genetic defect resulting in vWF dysfunction which may be mild or result in a significant bleeding diathesis [3]. Acquired von Willebrand syndrome (AVWS), a less prevalent disease, is a secondary structural or functional defect in vWF associated with a number of clinical conditions including autoimmune diseases and malignancies. Autoantibodies may interfere with vWF function or mediate
Table 1 Summary of laboratory findings on NM at presentation and after each course of Intravenous Immunoglobulin demonstrating transient improvement

| Laboratory parameter                      | Reference range   | Presentation | First course IVIg | Second course IVIg | Third course IVIg |
|-------------------------------------------|-------------------|--------------|-------------------|--------------------|-------------------|
| **Full Blood Count**                      |                   |              |                   |                    |                   |
| Haemoglobin                               | 12.4–16.7 g/dL    | 3.5          | 14.7              | 13.1               | 12.7              |
| Haematocrit                               | 0.35–0.49 UL      | 0.12         | 0.48              | 0.38               | 0.40              |
| Red cell Count                            | 3.8–5.5 × 10^9/L  | 1.29         | 5.56              | 4.88               | 4.43              |
| Mean Cell Volume                          | 79–100 fL         | 89.90        | 85.60             | 85.60              | 89.40             |
| Mean Cell Haemoglobin                     | 27–35 pg          | 27.10        | 26.50             | 26.80              | 28.70             |
| Mean Cell Haemoglobin concentration       | 29–37 g/dL        | 30.20        | 31.30             | 31.30              | 32.10             |
| White Cell Count                          | 4–12 × 10^9/L     | 4.52         | 5.14              | 4.70               | 2.62              |
| Platelet Count                            | 150–450 × 10^9/L  | 310          | 245               | 245                | 187               |
| Red cell distribution width               | 11.0–16.0         | 22.80        | 14.10             | 14.10              | 13.20             |
| **Reticulocyte production**               |                   |              |                   |                    |                   |
| Reticulocyte production index             | 1.00–1.25         | 2.2          |                   | 0.9                |                   |
| **Iron Studies**                          |                   |              |                   |                    |                   |
| Ferritin                                  | 20–300 ng/mL      | 7            |                   | 11                 |                   |
| **Coagulation studies**                   |                   |              |                   |                    |                   |
| INR                                       | 1.00–1.25         | 1.06         |                   | 1.02               |                   |
| Prothrombin Time                          | < 14 s            | 13.2         |                   | 11.8               | 14.6              |
| Activated Partial Thromboplastin Time     | 27–43 s           | 52.7         |                   | 35.4               |                   |
| Fibrinogen                                | 1.7–4.2 g/L       | 3.5          |                   | 3.8                |                   |
| **Factor VII levels**                     |                   |              |                   |                    |                   |
| Factor VIII                               | 50–150%           | 6            | 48 (7°)           | 78 (15°)           | 88 (22°)          |
| Factor VII inhibitor                      | Bethesda          | 0            |                   |                    | 0                 |
| **Von Willebrand Factor Screen**          |                   |              |                   |                    |                   |
| Von Willebrand Factor Activity           | 47.8–173.2%       | 15           |                   | 32 (6°)            |                   |
| Von Willebrand Factor Antigen            | 50–160%           | 10           | 52 (10°)          | 51 (14°)           | 43 (10°)          |
| **Platelet studies**                      |                   |              |                   |                    |                   |
| Agonist - ristocetin 0.5µg/mL            | No response       | Normal       | Normal            | Normal             |                   |
| Agonist - ristocetin 1.5µg/mL            | 60–110%           | 5            | 10                | 32 (10°)           |                   |
| ADP 5.0 µM                                | 60–100%           | 17           |                   |                    |                   |
| Epinephrine 10µg/mL                      | 60–110%           | 14           |                   |                    |                   |
| Collagen 2µg/mL                           | 60–110%           | 3            |                   |                    |                   |
| Arachidonic Acid                         |                  |              |                   |                    | Decreased         |
| **Platelet function analyser**            |                   |              |                   |                    |                   |
| Collagen/Epinephrine                     | 82–150            | > 300        |                   |                    |                   |
| Collagen /Adenosine diphosphate           | 62–100            | > 300        |                   |                    |                   |
| **Liver function tests**                  |                   |              |                   |                    |                   |
| Albumin                                  | 35–50 g/L         | 28           |                   |                    |                   |
| Bilirubin (unconjugated)                 | 3–6µmol/L         | 4            |                   |                    |                   |
| Bilirubin (conjugated)                   | 2–7 umol/L        | 3            |                   |                    |                   |
| AST                                       | 13–35 IU/L        | 8            |                   |                    |                   |
| ALT                                       | < 35 IU/L         | 3            |                   |                    |                   |
| IgM paraprotein                           | g/L               | 3            | 4                 | 4                  |                   |
increased clearance of the protein. Proteolysis may be associated with increased shear stress (for example, in cardiac valvular abnormalities). VWF may also be adsorbed onto transformed cells or platelets [4, 5]. Platelets play a fundamental role in primary haemostasis. Platelet abnormalities are often associated with mucocutaneous bleeding. Glanzmann’s thrombasthenia (GT) is a rare inherited platelet disorder caused by abnormalities in the GPIIb/IIIa (or αIIbβ3) receptor which binds fibrinogen, vWF, vitronectin and fibronectin to mediate platelet aggregation and clot retraction. Clinically, patients with GT present with a variable bleeding diathesis (most commonly epistaxis or menorrhagia) which may be severe requiring both repeated platelet and red cell transfusions. A similar clinical picture is seen in acquired Glanzmann’s thrombasthenia (AGT). Autoantibodies, again associated with various disease processes including malignancy, interfere with the function of the GPIIb/IIIa receptor [6].

Diagnosis of these acquired bleeding disorders can be challenging requiring high levels of clinical suspicion and specialized laboratory testing facilities. Treatment, in addition to management of the bleeding episodes, often requires immune modulation to suppress or remove autoantibodies.

Case presentation
An 81-year-old female patient, Mrs. NM, presented to casualty with a 3-year history of melaena, haematemesis and lethargy. Previous medical history recorded 8 uneventful deliveries and multiple tooth extractions which were not associated with excessive bleeding. There was also no family history of pathological bleeding. On clinical examination, the patient had signs of cardiac failure but was haemodynamically stable. She had diffuse cutaneous ecchymoses and significant pallor. There was no clinical evidence of haemarthrosis. There was no organomegaly or lymphadenopathy and the neurological system was grossly intact. Laboratory testing revealed a severe normocytic, normochromic anaemia. Her renal function was normal. Her albumin was mildly reduced but liver enzyme levels were not elevated. Coagulation testing revealed a prolonged activated partial thromboplastin time and a mildly prolonged prothrombin time which both corrected on mixing studies (data not shown). The Factor VIII levels and von Willebrand Factor antigen and activity (Ristocetin co-factor) levels were markedly reduced. Platelet aggregation studies showed a markedly reduced response to all platelet agonists including high dose ristocetin. Platelet function analyser studies demonstrated prolonged closure to both collagen/epinephrine and collagen/ADP (Table 1).

Gastroscopy revealed mild duodenal angiodysplasia with active bleeding. The patient received multiple blood and coagulation factor transfusions, anti-fibrinolytic agents and proton-pump inhibitors to control the bleeding. Monthly cycles of intravenous immunoglobulin (Polygam) of 40 g daily for 3 days were commenced and 3 cycles were administered. This regimen resulted in a clinical response with cessation of the bleeding and partial transient recovery of the vWF and Factor VIII levels (Fig. 1). Ristocetin response on platelet aggregometry demonstrated partial improvement. Following clinical stabilization, the patient was discharged to outpatient follow-up and subsequently relocated to a rural treatment facility.

Discussion and conclusions
Although the exact prevalence of AVWS is not known, it is a rare and potentially serious bleeding disorder with a multifactorial etiology [7]. AGT is equally rare requiring a high index of suspicion for timely recognition [6]. This case study describes a patient who presented with both conditions in the background of an underlying MGUS. The response to intravenous immunoglobulin (Polygam) therapy suggests that an autoimmune phenomenon was responsible for the development of the acquired bleeding disorders.
The diagnosis of acquired bleeding disorders is often difficult given the heterogeneity of the clinical presentation. A detailed individual and family bleeding history, clinical examination and laboratory diagnostic tests are required [8]. In suspected AVWS, vWF antigen (vWF:Ag) and activity levels and factor VIII activity levels should be measured. In many cases, all 3 of these parameters are reduced [9]. A disproportionate reduction in activity:antigen ratio for vWF may indicate the presence of inhibitory antibodies or decreased high molecular weight (HMW) multimers. Although more specialized testing may refine the diagnosis and help to clarify the underlying mechanism of disease (including vWF multimer analysis, vWF collagen-binding (vWF:CB) assays and vWF pro-peptide analysis), these are not available in our centre [10]. vWF pro-peptide, which measure vWF biosynthesis, was previously suggested as a specific marker for AVWS diagnosis. An increased propeptide/vWF:Ag ratio, therefore, may represent an accelerated clearance of plasma vWF. An increased ratio is, however, also present in certain patients with congenital type I vWD mediated by accelerated vWF clearance. A sandwich enzyme-linked immunosorbent assay to detect and quantify anti-VWF antibodies has been described but lacks specificity [11]. The treatment of AVWS involves control of the bleeding episodes, prevention of bleeding related to elective invasive procedure and the control of the underlying disease [12].

AGT is characterized by decreased or absent platelet aggregation in the presence of adequate platelet numbers. The GPIIb/IIIa receptor levels are normal but receptors are dysfunctional because of inhibition by auto-antibodies which develop in a number of different conditions including haematological malignancies and autoimmune states [6]. The hallmark laboratory finding in GT is reduced platelet aggregation to all agonists (collagen, ADP, arachidonic acid and epinephrine) on light-transmission-aggregometry (LTA) with a normal response to ristocetin. Platelet functional analyser studies show prolonged closure values to Collagen/ADP and Collagen/Epinephrine. Ristocetin mediates vWF binding to platelet receptor glycoprotein Ib (GPIb) with subsequent platelet aggregation. The patient in our case study demonstrated reduced responses to all the platelet agonists including ristocetin which probably reflected the significantly decreased vWF levels related to the co-existing AVWD. Various therapies including corticosteroids, chemotherapeutic agents, plasma exchange, intravenous immunoglobulin, recombinant factor VIIa and rituximab as well as platelet transfusions have been employed with variable success in patients with AGT [13, 14].

Despite 30 years of accumulated experience in the diagnosis and management of AVWS and AGT, many aspects of these syndromes remain unclear and these disorders are rare. The possibility of acquired bleeding disorders should, however, be considered in the appropriate clinical setting and in patients with atypical laboratory features, multiple underlying mechanisms may be contributory [4, 6].

Abbreviations
ADP: Adenosine diphosphate; AGT: Acquired Glanzmann thrombasthenia; AVWS: Acquired von Willebrand syndrome; GPIIb: Glycoprotein Ib; GT: Glanzmann thrombasthenia; IVIg: Intravenous immunoglobulin; LTA: Light-transmission-aggregometry; MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple Myeloma; PFA-100®: Platelet function analyzer; vWD: Von Willebrand Disease; vWF: Von Willebrand Factor

Availability of data and materials
All relevant data were included in this case study.

Authors’ contributions
SJL conceived the study and wrote the manuscript. MT, BJ and EP were responsible for clinical input and data collection. ESM assisted with critical review and wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This case study was approved by the Human Research Ethics Committee of
the University of the Witwatersrand. The participant provided consent to
participate and for publication. The ethics approval number is M1706103.

Consent for publication
The participant provided consent to publish.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Received: 23 June 2018 Accepted: 12 September 2018
Published online: 26 November 2018

References
1. Rajkumar SV, et al. International myeloma working group updated criteria
for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
2. Shimanovsky A, et al. Autoimmune manifestations in patients with multiple
myeloma and monoclonal gammopathy of undetermined significance. BBA
Clin. 2016;6:12–8.
3. James AH, Eikenboom J, Federici AB. State of the art: von Willebrand
disease. Haemophilia. 2016;22(Suppl 5):S54–9.
4. Federici AB, et al. Current diagnostic and therapeutic approaches to
patients with acquired von Willebrand syndrome: a 2013 update. Semin
Thromb Hemost. 2013;39(2):191–201.
5. Howard CR, et al. IgG kappa monoclonal gammopathy of undetermined
significance presenting as acquired type III Von Willebrand syndrome. Blood
Coagul Fibrinolysis. 2014;25(6):631–3.
6. Soh T, Botsford A, Soh M. Glanzmann’s thrombasthenia: pathogenesis,
diagnosis, and current and emerging treatment options. J Blood Med. 2015;
6:219–27.
7. Michiels JJ, et al. Acquired von Willebrand syndromes: clinical features,
aetiology, pathophysiology, classification and management. Best Pract Res
Clin Haematol. 2001;14(2):401–36.
8. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical
perspective. Semin Thromb Hemost. 2006;32(6):555–65.
9. De Jong A, Eikenboom J. Developments in the diagnostic procedures for
von Willebrand disease. J Thromb Haemost. 2016;14(3):449–60.
10. Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome:
experience from 2 years in a single laboratory compared with data from the
literature and an international registry. Semin Thromb Hemost. 2002;28(2):
227–38.
11. Siako C, et al. A new ELISA assay for diagnosis of acquired von Willebrand
syndrome. Haemophilia. 2003;9(3):303–8.
12. Federici AB. Acquired von Willebrand syndrome: is it an extremely rare
disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;
6(4):565–8.
13. Soh M, et al. Acquired Glanzmann’s thrombasthenia with optimal response
to rituximab therapy. Am J Hematol. 2011;86(8):715–6.
14. Tholoui E, et al. Acquired Glanzmann’s thrombasthenia without
thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J
Hematol. 2004;127(2):209–13.